June 01, 2022
Video
A clinician discusses the disease burden of reoccurring CDI, but sees a silver lining in the new investigational therapies potentially changing the treatment paradigm for the better.
May 29, 2022
A clinician is advocating for incorporating diagnostic stewardship practices within antimicrobial stewardship programs, which could someday lead to best practice guidelines on a larger scale.
May 27, 2022
Utilizing a newer technology, investigators wanted to see if a reduction in time led to clinically significant antimicrobial adjustments.
A multicenter study looked at treating these infections with omadacycline.
May 26, 2022
Article
The investigational, fully human IgG1 monoclonal antibody ADG20 prevented and treated infection with COVID-19 variants of concern.
A medical center wanted to review prescribing and documentation practices for their pharmacists.
May 24, 2022
RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.
With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.
May 23, 2022
A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2 antibiotics.
May 22, 2022
A health system piloted a program that explored having an infectious disease pharmacist aid in guiding treatment.
Monkeypox Symptoms in London Patients Differ from Prior Outbreaks
How COVID-19 Infiltrates and Inflames the Heart
Top 5 Infectious Disease Stories of the Week: July 1, 2022
Communities With More Racial Prejudice Have Worse Health Outcomes
